Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy: the FLEX Study

Overview

Journal JAMA Intern Med

Publisher American Medical Association

Specialty General Medicine

Date 2014 May 7

PMID 24798675

Citations 35

Authors

Douglas C Bauer

Ann Schwartz

Lisa Palermo

Jane Cauley

Marc Hochberg

Art Santora

Steven R Cummings

Dennis M Black

Affiliations

Soon will be listed here.

Abstract

Importance: Discontinuation of bisphosphonate therapy after 3 to 5 years is increasingly considered, but methods to monitor fracture risk after discontinuation have not been established.

Objective: To test methods of predicting fracture risk among women who have discontinued alendronate therapy after 4 to 5 years.

Design, Setting, And Participants: The prospective Fracture Intervention Trial Long-term Extension (FLEX) study randomized postmenopausal women aged 61 to 86 years previously treated with 4 to 5 years of alendronate therapy to 5 more years of alendronate or placebo from 1998 through 2003; the present analysis includes only the placebo group. Hip and spine dual-energy x-ray absorptiometry (DXA) were measured when placebo was begun (FLEX baseline) and after 1 to 3 years of follow-up. Two biochemical markers of bone turnover, urinary type 1 collagen cross-linked N-telopeptide (NTX) and serum bone-specific alkaline phosphatase (BAP), were measured at FLEX baseline and after 1 and 3 years.

Main Outcomes And Measures: Symptomatic spine and nonspine fractures occurring after the follow-up measurement of DXA or bone turnover.

Results: During 5 years of placebo, 94 of 437 women (22%) experienced 1 or more symptomatic fractures; 82 had fractures after 1 year. One-year changes in hip DXA, NTX, and BAP were not related to subsequent fracture risk, but older age and lower hip DXA at time of discontinuation were significantly related to increased fracture risk (lowest tertile of baseline femoral neck DXA vs other 2 tertiles relative hazard ratio, 2.17 [95% CI, 1.38-3.41]; total hip DXA relative hazard ratio, 1.87 [95% CI, 1.20-2.92]).

Conclusions And Relevance: Among postmenopausal women who discontinue alendronate therapy after 4 to 5 years, age and hip BMD at discontinuation predict clinical fractures during the subsequent 5 years. Follow-up measurements of DXA 1 year after discontinuation and of BAP or NTX 1 to 2 years after discontinuation are not associated with fracture risk and cannot be recommended.

Trial Registration: clinicaltrials.gov Identifier: NCT00398931.

Citing Articles

The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.

van den Bergh J, Geusens P, Appelman-Dijkstra N, van den Broek H, Elders P, De Klerk G Arch Osteoporos. 2024; 19(1):23.

PMID: 38564062 PMC: 10987374. DOI: 10.1007/s11657-024-01378-3.

Bisphosphonates and Atypical Femur Fractures: Is the Relationship Causal or Casual?.

Bal R, Ambade R, Singh N, Upadhyay P Cureus. 2023; 15(11):e48141.

PMID: 38046767 PMC: 10692760. DOI: 10.7759/cureus.48141.

The Use of Bone-Turnover Markers in Asia-Pacific Populations.

Vasikaran S, Thambiah S, Tan R, Loh T Ann Lab Med. 2023; 44(2):126-134.

PMID: 37869778 PMC: 10628755. DOI: 10.3343/alm.2023.0214.

Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies.

Wang M, Wu Y, Girgis C JBMR Plus. 2022; 6(6):e10629.

PMID: 35720669 PMC: 9189912. DOI: 10.1002/jbm4.10629.

UK clinical guideline for the prevention and treatment of osteoporosis.

Gregson C, Armstrong D, Bowden J, Cooper C, Edwards J, Gittoes N Arch Osteoporos. 2022; 17(1):58.

PMID: 35378630 PMC: 8979902. DOI: 10.1007/s11657-022-01061-5.

References

Recker R, Lewiecki E, Miller P, Reiffel J . Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009; 122(2 Suppl):S22-32. DOI: 10.1016/j.amjmed.2008.12.004. View

Delmas P, Munoz F, Black D, Cosman F, Boonen S, Watts N . Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24(9):1544-51. DOI: 10.1359/jbmr.090310. View

Genant H, Wu C, van Kuijk C, Nevitt M . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137-48. DOI: 10.1002/jbmr.5650080915. View

Vasikaran S, Eastell R, Bruyere O, Foldes A, Garnero P, Griesmacher A . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420. DOI: 10.1007/s00198-010-1501-1. View

Black D, Schwartz A, Ensrud K, Cauley J, Levis S, Quandt S . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24):2927-38. DOI: 10.1001/jama.296.24.2927. View

Rosen H, Dresner-Pollak R, Moses A, Rosenblatt M, Zeind A, Clemens J . Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int. 1994; 54(1):26-9. DOI: 10.1007/BF00316285. View

Barrett-Connor E, Swern A, Hustad C, Bone H, Liberman U, Papapoulos S . Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int. 2011; 23(1):233-45. PMC: 3249176. DOI: 10.1007/s00198-011-1546-9. View

Black D, Bauer D, Schwartz A, Cummings S, Rosen C . Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. N Engl J Med. 2012; 366(22):2051-3. PMC: 4015798. DOI: 10.1056/NEJMp1202623. View

Watts N, Geusens P, Barton I, Felsenberg D . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20(12):2097-104. DOI: 10.1359/JBMR.050814. View

10.

McNabb B, Vittinghoff E, Schwartz A, Eastell R, Bauer D, Ensrud K . BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013; 28(6):1319-27. DOI: 10.1002/jbmr.1864. View

11.

Watts N, Diab D . Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95(4):1555-65. DOI: 10.1210/jc.2009-1947. View

12.

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

13.

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

14.

Hochberg M, Ross P, Black D, Cummings S, Genant H, Nevitt M . Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999; 42(6):1246-54. DOI: 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U. View

15.

Ivaska K, Gerdhem P, Akesson K, Garnero P, Obrant K . Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007; 22(8):1155-64. DOI: 10.1359/jbmr.070505. View

16.

Eastell R, Vrijens B, Cahall D, Ringe J, Garnero P, Watts N . Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res. 2011; 26(7):1662-9. DOI: 10.1002/jbmr.342. View

17.

Favus M . Bisphosphonates for osteoporosis. N Engl J Med. 2010; 363(21):2027-35. DOI: 10.1056/NEJMct1004903. View

18.

Black D, Reiss T, Nevitt M, Cauley J, Karpf D, Cummings S . Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3 Suppl 3:S29-39. DOI: 10.1007/BF01623005. View

19.

Lewiecki E . Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis. 2012; 1(3):115-28. PMC: 3513863. DOI: 10.1177/2040622310374783. View

20.

McClung M, Harris S, Miller P, Bauer D, Davison K, Dian L . Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2012; 126(1):13-20. DOI: 10.1016/j.amjmed.2012.06.023. View